DONALDSON Co INC acquires Solaris Biotechnology S.r.l.
Snapshot
DONALDSON Co INC acquired Solaris Biotechnology S.r.l. for approximately EUR 41 million / $45.7 million (net of cash acquired) in November 2021. The transaction was structured as all cash. Solaris Biotechnology S.r.l. is a Headquartered in Porto Mantovano, Italy; U.S. operations in Berkeley, California-based Life Sciences business.
- Acquirer
- DONALDSON Co INC
- Target
- Solaris Biotechnology S.r.l.
- Value
- approximately EUR 41 million / $45.7 million (net of cash acquired)
- Date
- November 2021
- Type
- Full acquisition
- Status
- Ready
The deal at a glance
DONALDSON Co INC acquired Solaris Biotechnology S.r.l. for approximately EUR 41 million / $45.7 million (net of cash acquired), a transaction completed in November 2021, structured as all cash.
Solaris Biotechnology S.r.l. operates in Life Sciences, is based in Headquartered in Porto Mantovano, Italy; U.S. operations in Berkeley, California. Solaris designs and manufactures bioprocessing equipment, including bioreactors, fermenters and tangential flow filtration systems for use in pharma, food and beverage, biotechnology and other life sciences markets. Headquartered in Porto Mantovano, Italy, with U.S. operations based in Berkeley, California.
Expands Donaldson's bioprocessing equipment offering and establishes a Life Sciences manufacturing base in Europe.
Life Sciences segment (initially reported within IFS / Industrial Products)
No advisory firms have been disclosed for this transaction.